Net revenue, increased to $19.7 million in Q2 2024 from $13.0 million in Q2 2023, a 51.0% increase.
Gross profit, before fair value adjustments, increased to $7.1 million in Q2 2024 from $4.0.
Thanks in part to market share gains and increasing demand for high-quality cannabis at an affordable price in Canada, Cannara Biotech Inc. (OTCMKTS: LOVFF), the vertically integrated producer of premium-grade cannabis and derivative product offerings, reported record growth in revenue and net income for its fourth quarter of 2023.
Record Q4 and year end net revenues of $18.3 million and $57.6 million, representing a 53% and 60% increase compared to the same periods of 2022 Sequentially,.
Record Q4 and year end net revenues of $18.3 million and $57.6 million, representing a 53% and 60% increase compared to the same periods of 2022
Sequentially, Q4 showed significant growth over Q3.
Record Q4 and year end net revenues of $18.3 million and $57.6 million, representing a 53% and 60% increase compared to the same periods of 2022 Sequentially,.